Pyrrolidinyl Urea TrkA Crystal Forms for Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current TrkA inhibitors lack stability and efficacy in treating pain, cancer, inflammation, neurodegenerative diseases, and infectious diseases, with issues related to light, heat, and humidity sensitivity, as well as suboptimal pharmacokinetic properties.
Innovation Solution
Development of crystal forms A, B, C, D, E, and F of a TrkA inhibitor compound with specific X-ray diffraction patterns and thermal stability profiles, including preparation methods using solvents like alcohol, acetonitrile, and water to enhance stability and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional TrkA inhibitors are used, then TrkA enzyme inhibition is achieved, but stability against light, heat and humidity deteriorates
Solution Approach 1:
The patent applies parameter changes by developing multiple crystal forms (A, B, C, D, E, F) of the TrkA inhibitor compound, each with distinct X-ray diffraction patterns and stability characteristics. By changing the crystalline structure parameters, the invention achieves improved stability against light, heat and humidity while maintaining TrkA enzyme inhibition activity. Each crystal form represents a different physical state parameter that enhances overall reliability.
2Reliability
If conventional TrkA inhibitors are used, then TrkA enzyme inhibition is achieved, but pharmacokinetic properties deteriorate
Solution Approach 1:
The patent employs parameter changes by establishing six distinct crystal forms with different physical and chemical properties. These parameter variations in crystalline structure directly influence pharmacokinetic behavior, including solubility, dissolution rate, and bioavailability. The invention optimizes pharmacokinetic parameters through selective crystal form development, thereby improving ease of operation in therapeutic applications.
3Reliability
If multiple crystal forms are developed, then stability and bioavailability are improved, but device complexity increases
Solution Approach 1:
The patent applies copying by using X-ray powder diffraction (XRPD) patterns as unique fingerprints to identify and characterize each crystal form. Instead of performing complex structural analysis for each new crystal form, the invention creates reference diffraction patterns that can be copied and compared. This simplifies the characterization process by replacing complex device complexity with standardized analytical copying methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystal forms exhibit improved stability against light, heat, and humidity, with enhanced pharmacokinetic properties and bioavailability, offering effective TrkA enzyme inhibition and reduced drug-drug interactions.
Implementation Method 1
the X-ray powder diffraction pattern thereof comprises characteristic diffraction peaks at the following angles of 2θ: 13.40±0.20°, 18.71±0.20° and 19.51±0.20°
Implementation Method 2
the X-ray powder diffraction pattern thereof comprises characteristic diffraction peaks
Implementation Method 3
the differential scanning calorimetry curve of the crystal form A has an endothermic peak at 75.3±3.0 °C, 99.6±3.0 °C and 167.9±3.0 °C respectively and an exothermic peak at 132.3±3.0 °C
Implementation Method 4
the thermogravimetric analysis curve of the crystal form A shows a weight loss of 1.75 % occurred at 55.0±3.0 °C, and a weight loss of 3.08 % occurred at 100.0±3.0°C
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
Disclosed in the present invention are a crystal form of a TrkA inhibitor and a preparation method therefor, and an application thereof in preparation of drugs for treating diseases associated with pain, cancer, inflammation, neurodegenerative diseases, and certain infectious diseases.